Delcath Systems Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
790.00
1,069.00
1,747.00
1,992.00
2,715.00
3,407
Cost of Goods Sold (COGS) incl. D&A
1,590.00
1,249.00
770.50
550.00
701.00
1,009
Gross Income
800.00
180.00
976.50
1,442.00
2,014.00
2,398
SG&A Expense
28,245.00
16,243.00
15,783.50
17,882.00
20,179.00
29,469
EBIT
29,045.00
16,423.00
14,807.00
16,440.00
18,165.00
27,071
Unusual Expense
1,218.00
939.00
161.00
12,780.00
5,208.00
18,583
Non Operating Income/Expense
81.00
24.00
67.00
-
41.00
2,775
Interest Expense
-
-
-
14,328.00
21,703.00
7,959
Pretax Income
30,324.00
17,381.00
14,704.00
17,971.00
45,117.00
19,222
Consolidated Net Income
30,324.00
17,381.00
14,704.00
17,971.00
45,117.00
19,222
Net Income
30,324.00
17,381.00
14,704.00
17,971.00
45,117.00
19,222
Net Income After Extraordinaries
30,324.00
17,381.00
14,704.00
17,971.00
45,117.00
19,222
Net Income Available to Common
30,324.00
17,381.00
14,704.00
17,971.00
45,644.00
19,222
EPS (Basic)
13,717,861.60
5,152,673.49
2,549,019.61
1,854,640.98
3,250.00
0.72
Basic Shares Outstanding
0.00
0.00
0.00
0.00
14.00
26,705.40
EPS (Diluted)
13,720,763.54
5,150,872.16
2,548,477.22
1,855,452.11
3,251.31
0.72
Diluted Shares Outstanding
0.00
0.00
0.00
0.00
14.00
26,705.40
EBITDA
27,919.00
15,465.00
14,190.00
16,135.00
17,855.00
26,627
Non-Operating Interest Income
20.00
5.00
9.00
17.00
-
-
Preferred Dividends
-
-
-
-
527.00
-

About Delcath Systems

View Profile
Address
1633 Broadway
New York New York 10019
United States
Employees -
Website http://www.delcath.com
Updated 07/08/2019
Delcath Systems, Inc. is an oncology company, which focuses on the treatment of primary and metastatic liver cancers. It develops and commercializes Melphalan Hydrochloride for Injection, which is a proprietary product for use with the Delcath Hepatic Delivery System. The company was founded in August 1988 and is headquartered in New York, NY.